Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nucleolar protein 10 (NOL10) is a nucleolar RNA-binding protein involved in the maturation of the small subunit ribosomal RNA (SSU-rRNA) from the tricistronic transcript, playing a key role in ribosome biogenesis. NOL10 is required for proper nucleolar structure and function and localizes predominantly to the nucleolus in the cell nucleus. Elevated NOL10 expression is associated with aggressive clinicopathologic features and poor prognosis in breast cancer, particularly in triple-negative subtypes, and may serve as a biomarker of poor outcome and chemotherapy resistance. NOL10 is not considered a traditional therapeutic target such as a receptor, enzyme, or ion channel, and currently, no drugs are known to directly target it in therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleolar protein 10 (NOL10).